The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy (TT): Results from the international mRCC database consortium.
Toni K. Choueiri
Disclosure not yet available
Wanling Xie
Disclosure not yet available
Lauren Christine Harshman
Disclosure not yet available
Georg A. Bjarnason
Disclosure not yet available
Jennifer J. Knox
Disclosure not yet available
Mary J. MacKenzie
Disclosure not yet available
Lori Wood
Disclosure not yet available
Ulka N. Vaishampayan
Disclosure not yet available
Min-Han Tan
Disclosure not yet available
Sun Young Rha
Disclosure not yet available
Frede Donskov
Disclosure not yet available
Neeraj Agarwal
Disclosure not yet available
Christian K. Kollmannsberger
Disclosure not yet available
Scott A. North
Disclosure not yet available
Brian I. Rini
Disclosure not yet available
Daniel Yick Chin Heng
Disclosure not yet available